More about

Psoriatic Arthritis

News
September 27, 2022
2 min read
Save

Long-term efficacy of risankizumab maintained in psoriatic arthritis

Long-term efficacy of risankizumab maintained in psoriatic arthritis

MILAN — Long-term treatment with risankizumab maintained efficacy in psoriatic arthritis through 100 weeks, according to a study presented at the European Academy of Dermatology and Venereology Congress.

News
September 12, 2022
1 min read
Save

Risankizumab maintains skin, joint symptom resolution in psoriatic arthritis at 100 weeks

Risankizumab maintains skin, joint symptom resolution in psoriatic arthritis at 100 weeks

Adult patients with active psoriatic arthritis who received risankizumab reported sustained improvements in skin and joint symptoms at week 100 in two ongoing phase 3 trials, according to data released by AbbVie.

News
September 09, 2022
1 min read
Save

Top in rheumatology: Psoriatic arthritis guidance; cancer survival in autoimmune disease

Top in rheumatology: Psoriatic arthritis guidance; cancer survival in autoimmune disease

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis has updated its 2015 treatment recommendations of psoriatic arthritis to include the most up-to-date information.

News
August 31, 2022
2 min read
Save

Patients may consider tapering once psoriatic arthritis treatment goals are reached

Patients may consider tapering once psoriatic arthritis treatment goals are reached

Patients with psoriatic arthritis may consider tapering once treatment goals are reached, according to guidance from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis published in Nature Reviews Rheumatology.

News
August 30, 2022
4 min read
Save

‘PsA doesn’t happen by itself’: Importance of multidisciplinary management

‘PsA doesn’t happen by itself’: Importance of multidisciplinary management

For patients with psoriatic arthritis, collaboration between a dermatologist and rheumatologist is integral to receiving optimal care.

News
August 24, 2022
2 min read
Save

Guselkumab improves diverse psoriatic arthritis manifestations through 1 year

Guselkumab improves diverse psoriatic arthritis manifestations through 1 year

Guselkumab demonstrates sustained benefits for multiple, diverse manifestations of psoriatic arthritis through 1 year, according to data published in Rheumatology.

News
August 23, 2022
1 min read
Save

PEST score, BMI help predict psoriatic arthritis development in patients with psoriasis

PEST score, BMI help predict psoriatic arthritis development in patients with psoriasis

For patients with psoriasis, tools such as the Psoriasis Epidemiology Screening Tool can help predict the possibility of future psoriatic arthritis development, according to a study.

News
August 23, 2022
6 min read
Save

Safety Concerns Keep JAK Inhibitors a Second-line Treatment

Safety Concerns Keep JAK Inhibitors a Second-line Treatment

Janus kinase, or JAK, inhibitors have been used in the treatment of rheumatological disorders, including psoriatic arthritis. Their benefit in psoriatic skin disease is still being studied, however some safety concerns have kept the class of drugs as a second-line treatment option.

News
August 23, 2022
2 min read
Save

Getting (Re)acquainted with JAK

Getting (Re)acquainted with JAK

In this issue of Healio Psoriatic Disease, we focus on JAK inhibitors.

News
August 18, 2022
1 min read
Save

TYK2 inhibitors may offer pathway for more comprehensive inflammation therapy

TYK2 inhibitors may offer pathway for more comprehensive inflammation therapy

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

View more